Physiomics inks further contracts with Bicycle Therapeutics

Oncology drug development consultancy Physiomics said on Friday that it has been awarded two further contracts by existing client Bicycle Therapeutics.

Physiomics said the projects related to two of Bicycle's lead clinical assets and would build on earlier work completed by the firm on the assets in question.

The AIM-listed firm expects the contracts to be completed over the next six months.

Chief executive Dr Jim Millen said: "We are delighted that Bicycle continues to commission new projects with us and believe that it demonstrates the strength and depth of the relationship we have developed with this key client."

As of 0950 BST, Physiomics shares were up 4.21% at 6.30p.